If you are currently registered in PACS, click the PACS button above to log into PACS with your Binghamton University UserID and password
If you are not registered in PACS, please click here to Request an Account. NOTE: Under the Reason for Request field, please enter the following: Safety
The National Institutes of Health (NIH) and the Office of Biotechnology Activities require that universities maintain the highest level of scientific integrity and community safety in the review of research involving genetic engineering, the splicing together of DNA from different organisms. Strict rules have been established regarding types of experimentation allowable and under what circumstances different classes of experiments can be conducted. The NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) detail safety practices and containment procedures for basic and clinical research involving recombinant or synthetic nucleic acid molecules, including the creation and use of organisms and viruses containing recombinant or synthetic nucleic acid molecules.
If you have a protocol that requires review by the IBC please fill out and submit the smart form found in PACS (Link found at the top of this page) If there are no concerns found on initial review, the Research Compliance office will submit the protocol to the BioSafety Officer and the IBC for review. Typically, notification of required modifications or approval will be submitted to the PI within 14 calendar days of the IBC receiving the protocol. If the protocol is deemed exempt by the IBC, you may be notified sooner. All communication will be in the PACS system.
Protocols are approved for 3 years. Annual reports are required during that 3-year period. You can find the IBC Continuing Review in PACS. (Link found at the top of this page.) Please fill it out and submit the Continuing Review smart form 30 days prior to the annual anniversary of approval date. If you should need to continue your protocol past 3 years, a new protocol submission is required.
If you should make any modifications (including but not limited to: key personnel changes, lab location changes, changes to the originally planned research) at any time after your initial approval, you are required to notify the IBC of these modifications. You can Create an Amendment in PACS. (Link found at the top of this page.)
PACS Training Materials and STEP BY STEP Instructions
Online Biosafety Training Requirement
Beginning July 1, 2017 all undergraduate students, graduate students, and post-doctoral researchers participating on any IBC approved protocol will be required to complete the online Initial Biosafety Training. Binghamton University utilizes Collaborative Institutional Training Initiative (CITI) to complete online training programs. This same program is in use by many research-intensive universities nationwide.
Procedures for Online CITI Training
Click HERE and log in via the blue LOG IN button and then click "LOG IN THROUGH MY INSTITUTION" and chose SUNY-University at Binghamton. If you do not have an account chose I do not have an account and enter your pods
log in if requested.
To add the new course:
After you log in You will see the Main Menu:
Click Add a Course:
Skip questions numbered 1 through 3
For question 4, select: Initial Biosafety Training
Skip questions 5 through 7
You will need to accept the acknowledgment for the course prior to beginning.
For information or questions about your lab approval, contact: J. Kelly Donovan, Biosafety Officer by phone at 607-777-6834 or by email at email@example.com
Information about the IBC, contact: David Davies, committee chair, at firstname.lastname@example.org.
For all other questions or concerns please contact the Research Compliance Office by phone at 607-777-4664 or by email at email@example.com or Contact Nancy Lewis, Assistant Vice President of Research Compliance by phone at 607-777-3532 or by email at firstname.lastname@example.org
You can find the Select Agents, Pathogens and Toxins Notification of Possession form here.